TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00881218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.
Study: NCT01499953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux
Description: Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous
Study: NCT01688583

Intervention type: DRUG
Intervention: Fentanyl matrix
Description: Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
Study: NCT00974090

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)
Description: Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneli / Teneli + SU
Description: Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
Study: NCT00458341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, or apple juice. Participants are to receive a total of 42 doses of ataluren during each cycle, for a total of 84 doses of ataluren in both cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, or apple juice. Participants are to receive a total of 42 doses of ataluren during each cycle, for a total of 84 doses of ataluren in both cycles.
Study: NCT01329016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Women with GDM who require treatment will be given glyburide 2.5 mg. Medication will be given at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Women with GDM requiring treatment will be given metformin 500 mg. Medication will be administered at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide-Metformin combination
Description: Women with GDM requiring treatment will be given glyburide 2.5 mg with metformin 500 mg. Medications will be administered at least twice daily and equal doses will be given for each dosing time 3 days prior to the pharmacokinetic study day.
Study: NCT00672061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon or Placebo
Description: Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
Study: NCT00592761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mendelsohn Maneuver
Description: Mendelsohn Maneuver with Surface Electromyography
Study: NCT00866749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Starting Dose 25 mg/m\^2 by vein weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Starting Dose 2 mg by vein weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: Starting Dose 2000 International units/m2 by vein in week 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Methotrexate
Description: Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Starting Dose 1g/m2 by vein in weeks 1 and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Starting Dose 60 mg/m2 by mouth on days 1-14 of each month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10~+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m2 by vein in weeks 1, 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: 60 mg/m2 by mouth daily for two weeks
Study: NCT03930368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low GI diet with regular supplementation of raw corn starch
Description: Patients will be guided with a low GI diet with 60%\~70% of energy from carbohydrates. RCS constituted 30%\~50% of daily carbohydrate, and was supplemented as snacks every 4\~6 hours (25g per time) especially at night.
Study: NCT02287376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium for Oral Solution
Description: NSAID
Study: NCT03877107

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urinary symptoms profile questionnaire
Description: Validated questionnaire (international) with validated french translation, before and after lumbar puncture, and after surgery if surgery is realized

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Micturition calendar
Description: Micturition calendar on 2 consecutive days, before and after lumbar puncture, and after surgery if surgery is realized
Study: NCT02613351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scooting
Description: three-wheeled scooter (Monark 662, Monark Exercise AB Sweden) comprised of a single front wheel that provides steering and two rear wheels that create a wide base of support.
Study: NCT03659279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Get Organized
Description: Group intervention aiming to enhance time-management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with a PowerPoint presentation and a course manual, and information from the group leaders is intermixed with discussion among the participants and tasks to complete.
Study: NCT03184324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 placebo
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 placebo
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 placebo
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012 placebo
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole placebo
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole placebo
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole placebo
Description: tablet
Study: NCT02234323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: Administered as specified in arm description
Study: NCT01550913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sober Network Interpersonal Psychotherapy (IPT)
Description: IPT will be administered in 16 group 90-minute sessions over 18-20 weeks and 3 individual sessions (at the beginning, middle and end of treatment). These sessions will focus on improving your relationships with others, building sober relationships, setting goals, and increasing coping skills.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Women in the treatment as usual condition will either be referred to appropriate treatment in the community or continue their current substance use treatment.
Study: NCT04743479

Intervention type: DIAGNOSTIC_TEST
Intervention: high-resolution MRI/CT examinations
Description: Participants will undergo annual questionnaire survey, laboratory tests and high-resolution MRI/CT examinations of the pancreas. Any suspicious lesions will be further examined by endoscopic ultrasound (EUS).

Intervention type: DIAGNOSTIC_TEST
Intervention: high-resolution MRI/CT examinations
Description: Participants will undergo annual questionnaire survey, laboratory tests and high-resolution MRI/CT examinations of the pancreas. Any suspicious lesions will be further examined by endoscopic ultrasound (EUS).

Intervention type: DIAGNOSTIC_TEST
Intervention: high-resolution MRI/CT examinations
Description: Participants will undergo annual questionnaire survey, laboratory tests and high-resolution MRI/CT examinations of the pancreas. Any suspicious lesions will be further examined by endoscopic ultrasound (EUS).

Intervention type: DIAGNOSTIC_TEST
Intervention: high-resolution MRI/CT examinations
Description: Participants will undergo annual questionnaire survey, laboratory tests and high-resolution MRI/CT examinations of the pancreas. Any suspicious lesions will be further examined by endoscopic ultrasound (EUS).

Intervention type: DIAGNOSTIC_TEST
Intervention: high-resolution MRI/CT examinations
Description: Participants will undergo annual questionnaire survey, laboratory tests and high-resolution MRI/CT examinations of the pancreas. Any suspicious lesions will be further examined by endoscopic ultrasound (EUS).
Study: NCT02606461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor 60mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor 60mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03226405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation Program
Description: PN program improve access, timeliness and adherence with cancer treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: the standard of care provided by the institution
Study: NCT00147290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardiac Defibrillator
Description: Implantable cardiac defibrillator with programmable Fast Ventricular tachycardia detection (FVT) window

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardiac Defibrillator
Description: Implantable cardiac defibrillator with programmable Fast Ventricular tachycardia detection (FVT) window
Study: NCT02936063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical staples
Description: Closure of surgical wound at skin level with surgical staples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcuticular sutures
Description: Closure of surgical wound at skin level with subcuticular sutures
Study: NCT03457350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical negotiation
Description: trial to bypass severe cervical stenosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical negotiation
Description: trial to bypass severe cervical stenosis
Study: NCT02209155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-verapamil 75 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03152357

Intervention type: DEVICE
Intervention: ConforMIS iUni, iDuo, or iTotal (CR)
Description: ConforMIS iUni, iDuo, or iTotal (CR)
Study: NCT00028821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-methoxyestradiol
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01068392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Prednisolone
Description: OXALIPLATIN+PREDNISOLONE (OX-P)~D1 Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2hr~D1-5 Prednisolone 40-30-30 mg/day P.O~every 3 weeks
Study: NCT01109173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac Ophthalmic Suspension, 0.3%
Description: Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac Ophthalmic Suspension, 0.1%
Description: Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac Ophthalmic Suspension 0.3% Vehicle
Description: Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NEVANAC Vehicle
Description: Nepafenac vehicle, one drop in affected eye three times daily, for 16 days
Study: NCT01794364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 75 mg to 500 mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Correspondingly, placebo doses will be administered as suspension.
Study: NCT03042078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zero-fluoroscopic ablation
Description: Catheter ablation will be performed under the guidance of Ensite NavX and without the use of fluoroscopy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fluoroscopic ablation
Description: Catheter ablation will be performed under the guidance of Ensite NavX plus fluoroscopy.
Study: NCT01729858

Intervention type: DEVICE
Intervention: Ceramic-Ceramic
Description: Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.~Fifty percent of the recruited subjects will be given a ceramic-ceramic bridge at baseline.

Intervention type: DEVICE
Intervention: Metal-Ceramic
Description: Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.~Fifty percent of the recruited subjects will receive the metal-ceramic bridges at baseline.
Study: NCT01303965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Start on Day -3 and continue for 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Start on Day -3 and begin tapering on Day +100 until Day +180.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Start between Day +30 and +120 and continue for 1 year.
Study: NCT02191020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony & Acitretin Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin Capsules
Study: NCT01049243

Intervention type: DRUG
Group type: OTHER
Intervention: Fluocinonide Cream 0.1%
Description: 0.1% Cream, One Application, Twice Daily, 14 Days
Study: NCT03279874

Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured one-on-one interviews
Study: NCT03943862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2Share
Description: The peer-led group program contains of three lessons plus one booster session:~* Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weigh their pros and cons of (non-)disclosing a suicide attempt.~* Lesson 2: Different ways to disclose: Participants learn about the different ways to disclose and their respective pros and cons. Afterwards participants develop strategies to choose a person to disclose to, and discuss possible responses they might experience.~* Lesson 3: Telling your story: Participants learn how to tell their own story.~* In a booster session, participants will discuss their experiences with disclosure or non-disclosure.
Study: NCT00460057

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate
Description: Take two tablets (alendronate 10 mg) once weekly with a full glass of plain water in the morning after an overnight fast and to refrain from lying down or taking any other beverage or food for at least 1 h thereafter
Study: NCT03938077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Storytelling 4 Empowerment
Description: S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol \& drug use, HIV \& STIs, and tobacco prevention and cessation.
Study: NCT03877250

Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-Treatment Biopsy
Description: Participants screened for participation will include those with a diagnosis of advanced NSCLC who have undergone a pre-treatment biopsy prior to start of therapy with a PD-(L)1 inhibitor or who are medically able to undergo a biopsy if (1) no pre-treatment biopsy has been obtained and (2) no PD-(L)1 inhibitor has been started.

Intervention type: DIAGNOSTIC_TEST
Intervention: On-Treatment Biopsy
Description: All participants who receive at least 1 dose of PD-(L)1 inhibitor will be referred for a biopsy. The biopsy should be obtained within 4 weeks of first on-treatment imaging (usually performed \~6-9 weeks after beginning therapy) and will be performed in participants regardless of radiologic response.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy at Disease Progression
Description: All participants who develop disease progression after initial response to PD-(L)1 blockade will be considered for an additional, optional biopsy. Biopsies at disease progression are often obtained per standard of care within 4 weeks of documented progression on imaging and prior to the initiation of further systemic therapy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral Blood-Based Studies
Description: All participants will have peripheral blood obtained on Day 1 of cycles 1-4 (0, 3, 6, and 9 weeks). At each time point, peripheral blood sample will be collected pre-treatment and used for analysis of T cell subsets and TCR sequencing.
Study: NCT03672422

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Six ml of blood will be collected from patients in an EDTA tube. 2 ml saliva samples in Oragene DNA collection kits

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Six ml of blood will be collected from patients in an EDTA tube. 2 ml saliva samples in Oragene DNA collection kits

Intervention type: BEHAVIORAL
Intervention: Patient questionnaires
Description: Questionnaires will be completed at the baseline and annual follow-up visits to collect data that will define the demographics of the pediatric ARP and CP cohort, describe risk factors, presence of family history of acute and chronic pancreatitis, diabetes and pancreatic cancer and assess disease burden and sequelae.

Intervention type: BEHAVIORAL
Intervention: Patient questionnaires
Description: Questionnaires will be completed at the baseline and annual follow-up visits to collect data that will define the demographics of the pediatric ARP and CP cohort, describe risk factors, presence of family history of acute and chronic pancreatitis, diabetes and pancreatic cancer and assess disease burden and sequelae.

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva sample
Description: 2 ml saliva samples in Oragene DNA collection kits collected if no blood sample being collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva sample
Description: 2 ml saliva samples in Oragene DNA collection kits collected if no blood sample being collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample
Description: 50 ml of urine in collection container.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample
Description: 50 ml of urine in collection container.
Study: NCT04052568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will undergo up to four moderate to high dose psilocybin sessions. Dosing at the first session will be 20 mg. For subsequent sessions participants will either remain at their previous dose, or increase by increments of 5 mg up to a maximum of 30 mg.
Study: NCT00846885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan Succinate
Description: 100 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imitrex®
Description: 100 mg Tablet
Study: NCT02160704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enclomiphene citrate
Description: 25 mg daily for 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo daily for 16 weeks
Study: NCT04609059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M201-A Injection
Description: Active Substance: M201-A Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Placebo: M201-A Placebo Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)
Study: NCT01096355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study